On March 20, 2023 Genmab reported the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program (Press release, Genmab, MAR 20, 2023, View Source [SID1234629045]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share buy-back program is expected to be completed no later than March 31, 2023 and comprises up to 220,000 shares.

The following transactions were executed under the program from March 13, 2023, to March 17, 2023:

No. of shares Average price (DKK) Total value (DKK)
Accumulated through last announcement 133,000 342,851,540
March 13, 2023 8,000 2,447.52 19,580,160
March 14, 2023 8,000 2,507.62 20,060,960
March 15,2023 6,000 2,511.67 15,070,020
March 16, 2023 6,000 2,494.93 14,969,580
March 17, 2023 6,000 2,516.56 15,099,360

Total 34,000 84,780,080
Accumulated under the program 167,000 427,631,620
Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 710,416 shares as treasury shares, corresponding to 1.08% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 22, 2023.